Kupffer cell activation in normal and fibrotic livers increases portal pressure via thromboxane A2

被引:94
作者
Steib, Christian J.
Gerbes, Alexander L.
Bystron, Markus
den Winkel, Mark op
Haertl, Josef
Roggel, Frigga
Pruefer, Thomas
Goeke, Burkhard
Bilzer, Manfred
机构
[1] Univ Munich, Dept Med 2, Klinikum Grosshadern, D-81366 Munich, Germany
[2] Univ Munich, Inst Pathol, D-81366 Munich, Germany
[3] Univ Tubingen Hosp, Dept Anesthesiol, Tubingen, Germany
关键词
kupffer cells; inflammation; zymosan; portal hypertension; thromboxane A2; reactive oxygen species;
D O I
10.1016/j.jhep.2007.03.019
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: Cirrhotic patients show an increased risk of variceal bleeding upon bacterial infections. Kupffer cells (KC) constitute the first macrophage population to become activated by bacterial P-glucans and endotoxins derived from the gut. We therefore investigated whether and how KC activation increases portal pressure. Methods: KC in normal and fibrotic livers from bile duct ligated (BDL) rats were activated by the P-glucan component of zymosan in vivo and during isolated rat liver perfusion. Results: Activation of KC in normal livers resulted in a severalfold increase of portal pressure in vivo as well as in isolated perfused liver preparations. This increase and the accompanying 40-fold stimulation of hepatic prostaglandin F-2 alpha,/D-2 and thromboxane A(2) (TxA(2)) production in isolated perfused livers were attenuated by KC blockade. The TxA2 synthase inhibitor furegrelate and the TxA2 receptor antagonist BM 13.177 reduced the increase of portal perfusion pressure supporting TxA2 as pivotal vasoconstrictor released by activated KC. Importantly, a more pronounced vasopressor response in fibrotic livers was related to a raise in KC density and a 10-fold increase of TxA2 production after KC activation. Conclusions: KC activated by P-glucans increase portal pressure through the release of TxA2. This vasopressor response is augmented in BDL induced fibrosis. (C) 2007 European Association for the Study of the Liver. Published by Elsevier BN. All rights reserved.
引用
收藏
页码:228 / 238
页数:11
相关论文
共 30 条
[1]
Bergemeyer H. U., 1974, METHODS ENZYMATIC AN
[2]
PROGNOSTIC-SIGNIFICANCE OF BACTERIAL-INFECTION IN BLEEDING CIRRHOTIC-PATIENTS - A PROSPECTIVE-STUDY [J].
BERNARD, B ;
CADRANEL, JF ;
VALLA, D ;
ESCOLANO, S ;
JARLIER, V ;
OPOLON, P .
GASTROENTEROLOGY, 1995, 108 (06) :1828-1834
[3]
Bilzer M, 2005, SIGNALING PATHWAYS IN LIVER DISEASES, P45, DOI 10.1007/3-540-27194-5_4
[4]
Glutathione treatment protects the rat liver against injury after warm ischemia and Kupffer cell activation [J].
Bilzer, M ;
Baron, A ;
Schauer, R ;
Steib, C ;
Ebensberger, S ;
Gerbes, AL .
DIGESTION, 2002, 66 (01) :49-57
[5]
Complications of cirrhosis.: I.: Portal hypertension [J].
Bosch, J ;
García-Pagán, JC .
JOURNAL OF HEPATOLOGY, 2000, 32 :141-156
[6]
Crofford LJ, 1997, J RHEUMATOL, V24, P15
[7]
DISSOCIATION BETWEEN THE EFFECTS OF ZYMOSAN ON THE SYSTEMIC AND PULMONARY VESSELS OF THE RAT [J].
DAMAS, J ;
LAGNEAUX, D .
BRITISH JOURNAL OF PHARMACOLOGY, 1991, 104 (02) :559-564
[9]
BIOLOGICALLY-ACTIVE PRODUCTS OF STIMULATED LIVER MACROPHAGES (KUPFFER CELLS) [J].
DECKER, K .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1990, 192 (02) :245-261
[10]
The hernodynamic effects of zymosan in the perfused rat liver [J].
Derbocio, AM ;
Kelmer-Bracht, AM ;
Bracht, L ;
Bracht, A ;
Ishii-Iwamoto, EL .
VASCULAR PHARMACOLOGY, 2005, 43 (01) :75-85